Neimeth International Pharmaceuticals Plc. has announced that its Board of Directors will convene on Tuesday, October 21st, 2025, to review and approve the company’s third-quarter financial performance.
Company Secretary Chinenye Adekanbi informed the Nigerian Exchange Limited (NGX) and investors of the upcoming meeting in an official notice on Thursday.
“This is to notify Nigerian Exchange Limited (NGX) and the investing public that a meeting of the Board of Directors of Neimeth International Pharmaceuticals Plc. (the Company) is scheduled to hold on Tuesday, 21st October 2025 to consider and approve the Company’s Unaudited Financial Statements for the period ended 30th September 2025 (2025 Q3, UFS),” Adekanbi stated.
The pharmaceutical company has implemented a closed trading period in compliance with NGX regulations.
According to the notice, “In line with NGX’s Amended Closed Period Rules, the Company commenced a closed period from 1st October, 2025, and this will run up to twenty-four (24) hours after the outcome of the meeting and the 2025 Q3, UFS is released to the public.”
During this restricted period, company insiders are prohibited from trading the firm’s securities. “Consequently, Directors and other insiders of the Company have been duly notified not to deal in the Company’s securities during the closed period,” the announcement confirmed.
News.ng reports that the closed period will remain in effect until 24 hours after the financial statements are publicly released following the board meeting.
